Moderna, Inc. — Director's Dealing 2024

May 13, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2024-05-09

Reporting Person: Hoge Stephen (President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-05-09	Common Stock	M	522	—	Acquired	1486763	Direct
2024-05-10	Common Stock	S	255	$120.9573	Disposed	1486508	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-05-09	Restricted Stock Units	$	M	522	Disposed		Common Stock (522)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	4116	Indirect
Common Stock	151933	Indirect

Footnotes

F1: Restricted stock units convert into common stock on a one-for-one basis.

F2: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F3: These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

F4: 25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter.